Trial Profile
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2016
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 16 May 2016 Status changed from active, no longer recruiting to completed.
- 11 Mar 2013 Planned number of patients changed from 60 to 30 as reported by ClinicalTrials.gov.
- 11 Mar 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.